First author/year | Population | Sample size (n) | Age (years) | Male, n | Follow-up (months) | Cut-off (ng/mL) | Variables in multivariate model | Ref |
Schmid, 2017 | TAVI | 74 | 83 | 26 | 31 | 49 | STS score, RA area | 12 |
Stundl, 2017 | TAVI | 461 | 81 | 234 | 12 | 29 (development cohort); 33 (validation cohort) | LES, EuroSCORE II (ES II), STS-PROM, CRF, previous cardiac surgery, pulmonary hypertension, New York Heart Association class IV, NT-proBNP, LVEF | 13 |
Wernly, 2017 | TAVI | 274 | 80 | 125 | 12 | 10 | STS score, EuroSCORE, CRP, LVEDD, IDDM, LVEF, major vascular complication, TnT-I, sPAP, mean pressure gradient, 6 min walk test | 15 |
Lindman, 2015 | AVR (TAVI and surgical) | 345 | 78 | 194 | 23 | 33 | Glomerular filtration rate, sex, diabetes mellitus, obstructive lung disease, New York Heart Association functional class (III/IV vs I/II), aortic mean gradient | 14 |
AVR, aortic valve replacement; CRF, chronic renal failure; CRP, C-reactive protein; ES II, European System for Cardiac Operative Risk Evaluation II; IDDM, insulin-dependent diabetes mellitus; LES, logistic EuroSCORE; LVEDD, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro B-type natriuretic peptide; RA, right atrium; sPAP, systolic pulmonary arterial pressure; STS, Society of Thoracic Surgeons; STS-PROM, STS predicted risk of mortality; TAVI, transcatheter aortic valve implantation; TnT, troponin.